Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.
Type:
Grant
Filed:
July 20, 2015
Date of Patent:
May 23, 2017
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
Type:
Grant
Filed:
September 4, 2015
Date of Patent:
May 2, 2017
Assignee:
ALLERGAN, INC.
Inventors:
Yariv Donde, Jeremiah H. Nguyen, Karen M. Kedzie, Daniel W. Gil, John E. Donello, Wha-Bin Im
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Type:
Grant
Filed:
October 15, 2008
Date of Patent:
April 25, 2017
Assignee:
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Abstract: The present document is directed to a titanium dioxide scaffold comprising a hydrogel coating comprising a biologically active substance. Also disclosed is a method for producing a thin hydrogel coating on a titanium dioxide scaffold and uses of the hydrogel coated scaffolds as medical implants.
Type:
Grant
Filed:
September 18, 2013
Date of Patent:
April 25, 2017
Assignee:
CORTICALIS AS
Inventors:
S. Petter Lyngstadaas, Havard J. Haugen, Hanna Tiainen
Abstract: A gastroretentive composition comprises a mixture comprising an active ingredient component and an excipient component. The excipient component comprises a first water-soluble reaction product produced from a precursor comprising a vinyl group, and a copolymer of a polyalkylene glycol and a second water-soluble reaction product produced from a precursor comprising a vinyl group. A method of forming the gastroretentive composition comprises the steps of providing the active ingredient component and the excipient component, and mixing the active ingredient component and the excipient component to form a mixture. The mixture is aggregated to form an aggregation that is dry granulated to form a plurality of granules. The plurality of granules is processed to form the gastroretentive composition.
Abstract: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.
Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
Type:
Grant
Filed:
March 25, 2015
Date of Patent:
April 11, 2017
Assignee:
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.
Type:
Grant
Filed:
April 1, 2015
Date of Patent:
April 11, 2017
Assignee:
Celgene Corporation
Inventors:
Ming J. Chen, Ho-Wah Hui, Thomas Lee, Paul Kurtulik, Sekhar Surapaneni
Abstract: The present disclosure provides sulfhydryl-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include free sulfhydryl group, which can serve as a linker to attach biologically active molecules. For example, sulfhydryl groups can be used to conjugate biologically active polypeptides and/or metals to foam polymers. Methods for using sulfhydryl-modified polymers, such as for wound dressings, are also provided.
Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Abstract: The present invention is directed to compositions comprising a mixture comprising at least one isostearamide, at least one glycerol ester and water, and also to the use of these compositions as thickeners or shampoos, conditioners, shower gels, body cleaning compositions or skin cleaning compositions or for producing shampoos, conditioners, shower gels, body cleaning compositions or skin cleaning compositions.
Type:
Grant
Filed:
October 12, 2011
Date of Patent:
April 11, 2017
Assignee:
EVONIK DEGUSSA GMBH
Inventors:
Sascha Herrwerth, Oliver Springer, Ursula Westerholt
Abstract: Intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): Also, method comprising administering one or more pharmaceutically active substances to a patient in need thereof.
Type:
Grant
Filed:
January 12, 2016
Date of Patent:
March 28, 2017
Assignee:
DSM IP ASSETS, B.V.
Inventors:
Robert S. Ward, Shanger Wang, Li Li, Durgaprasad Chalasani, Patrick Kiser, Meredith Roberts Clark
Abstract: A nutritional supplement for a human, the supplement having a chelate comprised of an N-acetyl-L-cysteine ligand bonded to zinc to form a chelate ring. A method of treating a human for one or more of oxidative stress, cardiovascular disease, cerebrovascular disease, neurodegenerative diseases, Alzheimer's disease, ADHD, bipolar, schizophrenia, autism, dementia, and HIV in a human comprising administering an effective amount of a composition having N-acetyl-L-cysteine in a chelate formation with zinc. A compound having a chelate formulation with zinc being chelated by an N-acetyl-L-cysteine ligand.
Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the disclosure; and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1, an N-oxide, or salt thereof (e.g., as a component in the aforesaid composition). Also disclosed is a composition comprising: (a) at least one compound selected from the compounds of Formula 1 described above, N-oxides, and salts thereof; and at least one invertebrate pest control compound or agent.
Type:
Grant
Filed:
July 6, 2015
Date of Patent:
March 21, 2017
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Jeffrey Keith Long, Vann Gregory, Steven Gutteridge, Andrew Edmund Taggi, James Francis Bereznak
Abstract: The invention relates to a clay mineral for use as an agent for reducing the concentration of inorganic phosphate in liquids, in particular in bodily fluids or dialysis liquids, in order to treat hyperphosphatemia, in particular in a renal replacement therapy, wherein before use, the clay mineral is thermally treated at a temperature between 400° C. and 800° C., preferably between 500° C. and 700° C., in particular preferably at 550° C., over a time period of 60 min to 240 min, preferably 90 min to 180 min, in particular preferably 120 min.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
March 7, 2017
Assignee:
Fraunhofer-Gesellschaft zur Förderung der angewandten Furschung e.V.
Inventors:
Steffen Mitzner, Claus Kerkhoff, Frank Emmrich, Anne Breitruck, Peggy Bodammer, Gerd Kruger, Rainer Dallwig
Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
February 28, 2017
Assignee:
Saniona A/S
Inventors:
Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
Abstract: An aerosol antiperspirant composition is provided. The aerosol antiperspirant composition includes a propellant having a concentration from 70% to 90% by weight of the aerosol antiperspirant composition and an antiperspirant composition. The antiperspirant composition includes one or more liquid materials, wherein the one or more liquid materials comprise one or more non-volatile silicone fluids having a concentration from 40% to about 70% by weight of the antiperspirant composition, an antiperspirant active particulate, one or more non-antiperspirant active particulates that are substantially inert, wherein the one or more non-antiperspirant active particulates have a concentration from 10% to 30% by weight of the antiperspirant composition. The antiperspirant composition has a total particulate concentration from 30% to about 60% by weight of the antiperspirant composition.
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
February 28, 2017
Assignee:
The Procter & Gamble Company
Inventors:
David Frederick Swaile, Rajeev Kumar Passi, Ann Christine Zoller, Elton Luis Menon
Abstract: This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.
Type:
Grant
Filed:
August 10, 2012
Date of Patent:
February 21, 2017
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Syed Hossainy, Dariush Davalian, Mikael Trollsas, John Stankus, Jinping Wan
Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Type:
Grant
Filed:
April 6, 2015
Date of Patent:
February 21, 2017
Assignees:
President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
Inventors:
Kenneth C. Anderson, James E. Bradner, Edward Franklin Greenberg, Teru Hideshima, Nicholas Paul Kwiatkowski, Ralph Mazitschek, Stuart L. Schreiber, Jared Shaw, Stephen J. Haggarty